Protocol Ledger

NCT05881837 · Phase II · COMPLETED

A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Interventional Phase II clinical trial protocol NCT05881837 sponsored by Fujian Shengdi Pharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-13 Enrollment: 249 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05881837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)249 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05881837
Protocol FieldVerified Registry Value
NCT IdentifierNCT05881837
Consolidated Lead SponsorFujian Shengdi Pharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment249 participants (ACTUAL)
Registered Start Date2023-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI